Group 1: Financial Performance - The company achieved double-digit growth in both revenue and net profit in Q3 2024, driven by a focus on core products and multi-channel strategies, including e-commerce [2] - Online sales account for approximately 66.67% of total revenue, while offline sales make up about 33.33%, aligning with industry averages [3] Group 2: Product Innovation - New products launched in the health monitoring and respiratory support sectors are expected to drive future revenue growth, including a blood glucose and uric acid testing device and a continuous glucose monitor [2] - The company introduced several innovative respiratory support products, such as the second-generation sleep apnea machine and portable sleep apnea devices [2] Group 3: Seasonal Sales Trends - Sales are typically stronger in Q1 and Q4 due to increased demand during the winter months and promotional events like Double Eleven and Double Twelve [3] - Sales in Q2 and Q3 may decline due to reduced foot traffic in offline channels during the hot summer months [3] Group 4: Sales Strategy and Future Plans - The company aims to maintain stable sales expense ratios while enhancing e-commerce operational efficiency and expanding hearing aid business revenue [3] - Future expansion plans for the hearing aid segment will adapt to market conditions, with a commitment to becoming a leading hearing chain enterprise in China [4]
可孚医疗(301087) - 2024年11月21日投资者关系活动记录表